2013 Annual Report

Total Page:16

File Type:pdf, Size:1020Kb

2013 Annual Report 2013 Annual Report Making a Difference in People’s Lives Table of Contents Page Our business 2 Management’s discussion and analysis of financial condition and results of operations 15 Management 32 Principal shareholders 37 Certain relationships and related party transactions 38 Description of certain financing arrangements 41 Risk factors 47 Glossary 67 Index to financial statements F-1 Our Business Overview ConvaTec is a global medical products and technologies company, with leading market positions in ostomy care, wound therapeutics, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. We have over 8,000 employees, with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. For the 12 months ended December 31, 2013, we had net sales of $1,700.7 million and adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) of $549.6 million. ConvaTec has a history of innovation and industry leadership that spans over 35 years: Our AQUACEL® dressings feature a unique wound contact layer that transforms into a gel on contact with wound fluid, creating an optimal environment for wound healing and minimizing the risk of infection. We pioneered modern ostomy care with the development of moisture-absorbing medical adhesives, and today our ostomy products are designed with ConvaTec Moldable Technology™ for clinically superior performance. We are the world’s leading provider of disposable infusion sets to manufacturers of insulin pumps. Our Strengths Leading Position in Attractive, Growing Markets We are one of the top three global leaders in many of our core segments. We have leading market shares globally in infusion devices, fecal management and several advanced wound care segments; in ostomy care, we have leading share in several markets globally and the second largest share in North America. Additionally, we have brands that are widely recognized and respected by health care providers and care givers alike. Our broad product portfolio, brand equity and reputation for quality create significant competitive advantages. We operate in attractive and growing markets. Underlying health care trends —aging populations, growing incidence of disease and expanded adoption of advanced therapies globally — will create additional demand across all markets. The Wound Therapeutics market is expected to grow 5-6% per annum over the next five years, driven by an increase in the number of addressable wounds and a shift from traditional products to more advanced therapies. The Ostomy Care market has an expected growth rate of 3-4% per annum over the next five years, driven by favorable demographics. The Continence & Critical Care (“CCC”) market has an expected growth rate of 4-5% per annum over the next five years, driven by increases in general, non-elective care consumption and reimbursement coverage. The Infusion Devices market is expected to grow 5-6% per annum over the next five years, driven by the increasing prevalence of diabetes and expanded reimbursement coverage for insulin pump therapy. Large, Diversified and Recurring Revenue Base Derived from Medical Consumables Our business is highly diversified across countries, end markets, product lines, customers and payers. For the twelve month period ended December 31, 2013, Ostomy Care, Wound Therapeutics, Continence & Critical Care, and Infusion Devices segments generated 36%, 31%, 18%, and 15% of total net sales, respectively. Our products are marketed and distributed to a wide range of customers, including health care providers, patients and manufacturers. For the year ended December 31, 2013, no single customer represented more than 10% of our net sales, and no single product represented more than 15% of net sales. A majority of our business is derived from medical consumables and tied to long-term customer relationships, generating consistent, recurring revenues. The Ostomy Care segment in particular is characterized by a large base of loyal long-term patients, with relationships spanning 10-15 years or more. 2 ConvaTec Healthcare B S.a.r.l. and Subsidiaries Deep Product Pipeline and Accelerating New Product Revenue We have been a leader in new product development for over 35 years. Our long and successful history of product innovation includes Hydrofiber® Technology for wound care (introduced in 1996), Moldable Technology™ in ostomy (introduced in 2002), and Flexi-Seal® for fecal management (introduced in 2004). Recent product launches continue this trend, with AQUACEL® Foam the most successful launch in our history. We have a revitalized core product portfolio and a strong pipeline of innovative new products that will drive future growth. Successful Acquisitions with Additional M&A Opportunity We have a strong track record of successful acquisitions, with a focus on high-growth, low-risk targets that are easily integrated and provide immediate value creation. We continue to look for acquisitions in three strategic areas: getting closer to customers through direct-to-consumer channels, enhancing our product portfolio and expanding in emerging markets. We believe there is a significant opportunity to supplement organic growth with such acquisitions. Strong Emerging Market Growth We have a growing presence in emerging markets, with double-digit compound annual growth rates since 2010. For the year ended December 31, 2013, sales in emerging markets represented 13.6% of total revenues. Emerging markets have attractive growth characteristics, driven by an expanding middle class, increasing access to health care and aging populations with longer life expectancies. We are well positioned for growth as emerging markets adopt advanced medical treatments. Growing Direct-to-Customer Capabilities With the 180 Medical and Symbius Medical acquisitions in the US and similar acquisitions in the UK, we have growing direct-to-customer capabilities. These capabilities enable us to develop stronger relationships with our customers, build brand loyalty and generate additional revenue by leveraging the sales model across our entire portfolio. Highly Efficient Global Manufacturing We have a highly efficient and strategically located manufacturing network, with 11 sites in 8 countries, many of which are in relatively low-cost labor markets. This gives us significant operational flexibility and the ability to continuously drive improvements in productivity and overall profitability. Our broad distribution network provides an important complement to our manufacturing capabilities, together enabling us to efficiently serve our global customer base. Excellent Financial Results and Superior Cash-Flow Generation Fiscal 2013 marked the second straight year of accelerated business performance for ConvaTec. With most of our products used in necessary and non-elective medical care, our business has strong and predictable cash flow generation characteristics. We have the ability to continue to generate significant cash flow based on our competitive strengths and the relatively low level of capital expenditure and working capital required to maintain our underlying businesses. Increased operating efficiencies and productivity savings have contributed to margin expansion and are allowing us to invest in growth-generating activities. Our Strategy We intend to drive sustained revenue and EBITDA growth by extending our market leadership, capturing new revenue streams and continuously improving productivity. Extend Market Leadership In Ostomy Care, we are focused on establishing ConvaTec as the clear market leader by developing even stronger relationships with customers and by regularly introducing new products. We have a highly disciplined approach to attracting new ostomy customers and earning their loyalty. We also continue to focus on differentiating our ostomy products through our proprietary ConvaTec Moldable Technology™, which is clinically proven to prevent leakage and 3 ConvaTec Healthcare B S.a.r.l. and Subsidiaries skin complications. In addition, we are leveraging our skin care and clothing accessories to capture incremental revenue and broaden relationships with customers. In Wound Therapeutics, we are leveraging the AQUACEL® brand into new market segments and medical indications, introducing a variety of new products that support infection control. In particular, we are focused on taking significant share of the nearly $1 billion market for foam dressings with our new AQUACEL® Foam offering and on expanding our share of the global silver dressing market with the launch of our new AQUACEL® Ag+ dressings. In Continence & Critical Care, we are extending our leadership in fecal management with continuous product enhancements and by helping health care providers respond to the challenge of hospital-acquired infections. In addition we are focused on taking significant share in the $1.5 billion market for intermittent self-catherization with our new GentleCath™ portfolio. In Infusion Devices, we continue to expand our position as the leading provider of disposable infusion sets to insulin pump manufacturers and pursue broader strategic partnerships with OEMs (original equipment manufacturers). In addition, we are expanding our presence in other continuous infusion therapies, including treatments for Parkinson’s disease and pain management. Launch New Products W e continue to innovate
Recommended publications
  • Xtrackers Etfs
    Xtrackers*/** Société d’investissement à capital variable R.C.S. Luxembourg N° B-119.899 Unaudited Semi-Annual Report For the period from 1 January 2018 to 30 June 2018 No subscription can be accepted on the basis of the financial reports. Subscriptions are only valid if they are made on the basis of the latest published prospectus of Xtrackers accompanied by the latest annual report and the most recent semi-annual report, if published thereafter. * Effective 16 February 2018, db x-trackers changed name to Xtrackers. **This includes synthetic ETFs. Xtrackers** Table of contents Page Organisation 4 Information for Hong Kong Residents 6 Statistics 7 Statement of Net Assets as at 30 June 2018 28 Statement of Investments as at 30 June 2018 50 Xtrackers MSCI WORLD SWAP UCITS ETF* 50 Xtrackers MSCI EUROPE UCITS ETF 56 Xtrackers MSCI JAPAN UCITS ETF 68 Xtrackers MSCI USA SWAP UCITS ETF* 75 Xtrackers EURO STOXX 50 UCITS ETF 80 Xtrackers DAX UCITS ETF 82 Xtrackers FTSE MIB UCITS ETF 83 Xtrackers SWITZERLAND UCITS ETF 85 Xtrackers FTSE 100 INCOME UCITS ETF 86 Xtrackers FTSE 250 UCITS ETF 89 Xtrackers FTSE ALL-SHARE UCITS ETF 96 Xtrackers MSCI EMERGING MARKETS SWAP UCITS ETF* 111 Xtrackers MSCI EM ASIA SWAP UCITS ETF* 115 Xtrackers MSCI EM LATIN AMERICA SWAP UCITS ETF* 117 Xtrackers MSCI EM EUROPE, MIDDLE EAST & AFRICA SWAP UCITS ETF* 118 Xtrackers MSCI TAIWAN UCITS ETF 120 Xtrackers MSCI BRAZIL UCITS ETF 123 Xtrackers NIFTY 50 SWAP UCITS ETF* 125 Xtrackers MSCI KOREA UCITS ETF 127 Xtrackers FTSE CHINA 50 UCITS ETF 130 Xtrackers EURO STOXX QUALITY
    [Show full text]
  • Parker Review
    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
    [Show full text]
  • Schroder UK Mid Cap Fund
    Schroder UK Mid Ca p Fund plc Half Year Report and Accounts For the six months ended 31 March 2020 Key messages – Portfolio of “high conviction” stocks aiming to provide a total return in excess of the FTSE 250 (ex-Investment Companies) Index and an attractive level of yield. – Dividend has tripled since 2007 as portfolio investments have captured the cash generative nature of investee companies, in a market where income has become an increasingly important part of our investors’ anticipated returns. – Provides exposure to dynamic mid cap companies that have the potential to grow to be included in the FTSE 100 index, which are at an interesting point in their life cycle, and/or which could ultimately prove to be attractive takeover targets. – Proven research driven investment approach based on the Manager’s investment process allied with a strong selling discipline. – Managed by Andy Brough and Jean Roche with a combined 50 years’ investment experience 1, the fund has a consistent, robust and repeatable investment proces s. 1Andy Brough became Lead Manager on 1 April 2016 . Investment objective Schroder UK Mid Cap Fund plc’s (the “Company”) investment objective is to invest in mid cap equities with the aim of providing a total return in excess of the FTSE 250 (ex -Investment Companies) Index. Investment policy The strategy is to invest principally in the investment universe associated with the benchmark index, but with an element of leeway in investment remit to allow for a conviction-driven approach and an emphasis on specific companies and targeted themes. The Company may also invest in other collective investment vehicles where desirable, for example to provide exposure to specialist areas within the universe.
    [Show full text]
  • DATABANK INSIDE the CITY SABAH MEDDINGS the WEEK in the MARKETS the ECONOMY Consumer Prices Index Current Rate Prev
    10 The Sunday Times February 10, 2019 BUSINESS Liam Kelly LETTERS 56-year-old chairman of before Serco and others got Send your letters, including executive had the audacity to arrangements a business has. Mrs M&S awaits her love sausage housebuilder Taylor Wimpey into a pickle for overcharging SIGNALS full name and address, describe me as a “dangerous For those already using a has been keen to link his the government to tag AND NOISE . to: The Sunday Times, threat” to the company. supported package, there is Much derision for Marks & Prufrock wonders name to several recruitment criminals, ushering in a 1 London Bridge Street, Calantzopoulos has likely to be no additional cost. Spencer after the high street whether Rowe, 51, plans to processes, including the dark period for outsourcers. London SE1 9GF. Or email: spearheaded PMI’s drive for For those using spreadsheets, stalwart unveiled a heart- treat the Mrs M&S in his life — chairmanships of John Lewis Beeston knows how tricky letters@sunday-times.co.uk safer products. That doesn’t bridging products are shaped “love sausage” as a his wife, Jo, an ardent Marks Partnership and the suit hire recruitment can be: he’s on Letters may be edited make him a hypocrite, but a available at about £20 a year. treat for a romantic breakfast shopper — to a love sausage chain Moss Bros. the nominations committee realist. André is an engineer: Our MTD service is live to on Valentine’s Day. on Thursday. He has been at Taylor of the Premier League, careful, methodical, logical.
    [Show full text]
  • Your Guide Directors' Remuneration in FTSE 250 Companies
    Your guide Directors’ remuneration in FTSE 250 companies The Deloitte Academy: Promoting excellence in the boardroom October 2018 Contents Overview from Mitul Shah 1 1. Introduction 4 2. Main findings 8 3. The current environment 12 4. Salary 32 5. Annual bonus plans 40 6. Long term incentive plans 52 7. Total compensation 66 8. Malus and clawback 70 9. Pensions 74 10. Exit and recruitment policy 78 11. Shareholding 82 12. Non-executive directors’ fees 88 Appendix 1 – Useful websites 96 Appendix 2 – Sample composition 97 Appendix 3 – Methodology 100 Your guide | Directors’ remuneration in FTSE 250 companies Overview from Mitul Shah It has been a year since the Government announced its intention to implement a package of corporate governance reforms designed to “maintain the UK’s reputation for being a ‘dependable and confident place in which to do business’1, and in recent months we have seen details of how these will be effected. The new UK Corporate Governance Code, to take effect for accounting periods beginning on or after 1 January 2019, includes some far reaching changes, and the year ahead will be a period of review and change for many companies. Remuneration committees must look at how best to adapt to an expanded remit around workforce remuneration, as well as a greater focus on how judgment is used to ensure that pay outcomes are justified and supported by performance. Against this backdrop, 2018 has been a mixed year in the FTSE 250 executive pay environment. In terms of pay outcomes, the picture is relatively stable. Overall pay levels have fallen for FTSE 250 chief executives and we have seen continued momentum in companies adopting executive alignment features such as holding periods, as well as strengthening shareholding guidelines for executives.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • The UK Private Equity IPO Report
    THE UK PRIVATE EQUITY IPO REPORT Private equity-backed IPOs: 1 January 2009 – 31 December 2017 IN ASSOCIATION WITH 2 | THE UK PRIVATE EQUITY IPO REPORT CONTENTS FOREWORD 03 HISTORIC ANALYSIS OF PRIVATE EQUITY-BACKED IPOS IN THE UK 04 BETWEEN 1 JANUARY 2009 AND 31 DECEMBER 2017 VOLUME AND VALUE OF PRIVATE EQUITY-BACKED IPOS LISTING IN THE UK 05 TOP 10 PRIVATE EQUITY-BACKED IPOS 06 INDUSTRIES 07 FREE FLOAT 12 USE OF PROCEEDS 13 PRICING 14 PERFORMANCE 15 ANALYSIS OF ACTIVE PRIVATE EQUITY HOUSES BY SIZE 17 LOCK-UP PERIODS 18 HOLDING PERIODS 20 PRIVATE EQUITY-BACKED IPO ACTIVITY IN 2017 21 APPENDIX 23 PRIVATE EQUITY-BACKED IPOS 1 JANUARY 2009 - 31 DECEMBER 2017 23 METHODOLOGY 31 CONTACTS 32 3 | THE UK PRIVATE EQUITY IPO REPORT FOREWORD Public markets have long been an important exit route for private equity houses selling their stakes into the companies they have backed, yet little research has been conducted into how these businesses perform after they have floated. This report, published by the BVCA and PwC, provides an historic analysis of private equity-backed IPOs in the UK between 1 January 2009 and 31 December 2017. It looks at a number of metrics including the use of proceeds, pricing and performance to build a picture of the IPO market and the key trends with the market. The performance numbers are particularly revealing as they show that private equity-backed IPOs are trading on average 43.9% higher than their offer price for the period from IPO to 31 December 2017 compared to the non-private equity-backed IPOs of the same period which are trading at an average of 26.6% higher.
    [Show full text]
  • Improving the Lives of the People We Touch
    Improving the lives of the people we touch ConvaTec Group Plc Annual Report and Accounts 2018 2018 highlights Financial highlights1 Revenue Operating profit Earnings per share $1,832m +3.8% $268m +8.0% $0.11 +37.5% ,m m . ,m m . Adjusted EBIT2 Adjusted EBIT margin Adjusted earnings per share $429m -6.0% 23.4.% $0.16 m . . m . . 1. Certain financial measures in this Annual Report and Accounts, including adjusted performance measures above, are not prepared in accordance with IFRS. All adjusted performance measures are reconciled to the most directly comparable measure prepared in accordance with IFRS on pages 66 to 71. 2. Adjusted EBIT is equivalent to adjusted operating profit as reconciled on pages 68 to 69. Contents Overview Governance Financial statements Other information IFC Financial highlights and 72 Governance report at 124 Independent auditor’s 180 Shareholder information contents a glance report to the members 01 Introduction 73 Chairman’s governance of ConvaTec Group Plc 02 Our business at a glance letter 133 Consolidated Statement 04 Our investment case 74 Governance in action of Profit or Loss 75 Board statements and how 134 Consolidated Statement Strategic report we have applied the Code of Comprehensive Income 05 Strategic report overview 78 Leadership 135 Consolidated Statement 06 Chairman’s letter 80 Board of Directors of Financial Position 08 Chief Executive Officer’s 84 Effectiveness 136 Consolidated Statement review 86 Nomination Committee of Changes in Equity 12 Our market environment report 137 Consolidated
    [Show full text]
  • Holdings—Artisan International Small-Mid Fund
    Artisan International Small-Mid Fund Holdings As of 31 March 2020 Portfolio Holdings Quantity Security Name/Description Price Book Total Market Value Book Pct Assets (%) 556,077 Abcam PLC 14.28 7,942,769.54 0.50 330,602 ACADIA Pharmaceuticals Inc 42.25 13,967,934.50 0.88 733,643 Afya Ltd 19.06 13,983,235.58 0.89 126,083 Agios Pharmaceuticals Inc 35.48 4,473,424.84 0.28 2,060,867 AIXTRON SE 8.78 18,099,561.49 1.15 52,248 Alcon Inc 51.03 2,666,321.30 0.17 41,137 ALK-Abello A/S 227.41 9,355,090.70 0.59 473,743 Alkermes PLC 14.42 6,831,374.06 0.43 1,659,119 Almirall SA 11.59 19,222,951.38 1.22 78,841 Alnylam Pharmaceuticals Inc 108.85 8,581,842.85 0.54 690,713 Altus Group Ltd 25.94 17,914,463.50 1.13 459,233 Amarin Corp PLC 4.00 1,836,932.00 0.12 774,611 Ambu A/S 24.37 18,878,174.19 1.20 137,197 Applied Therapeutics Inc 32.69 4,484,969.93 0.28 170,372 Aprea Therapeutics Inc 34.76 5,922,130.72 0.38 121,082 Argenx SE 134.93 16,337,543.38 1.03 123,052 Ariake Japan Co Ltd 62.84 7,733,059.49 0.49 136,929 ASOS PLC 14.81 2,027,698.28 0.13 514,003 Aston Martin Lagonda Global Holdings PLC 2.45 1,260,236.90 0.08 128,913 Atos SE 67.67 8,723,084.19 0.55 1,245,970 Auto Trader Group PLC 5.43 6,771,404.11 0.43 386,175 AVEVA Group PLC 43.18 16,674,996.34 1.06 1,260,800 Azbil Corp 25.98 32,755,216.69 2.07 3,465,136 B&M European Value Retail SA 3.41 11,831,480.87 0.75 156,915 Baloise Holding AG 131.26 20,596,262.63 1.30 108,140 Basler AG 41.18 4,453,444.53 0.28 316,966 Beijer Ref AB 18.01 5,708,330.96 0.36 3,602 Belimo Holding AG 6,487.29 23,367,224.49 1.48
    [Show full text]
  • FTSE Russell Publications
    FTSE Russell Publications 19 November 2018 FTSE 250 Indicative Index Weight Data as at Closing on 28 September 2018 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.34 UNITED Capital & Counties Properties 0.51 UNITED Esure Group 0.21 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.13 UNITED Card Factory 0.16 UNITED Euromoney Institutional Investor 0.19 UNITED KINGDOM KINGDOM KINGDOM AA 0.15 UNITED Centamin 0.3 UNITED F&C Commercial Property Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.32 UNITED Charter Court Financial Services Group 0.12 UNITED F&C Global Smaller Companies 0.22 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.54 UNITED Cineworld Group 0.82 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.68 UNITED City of London Investment Trust 0.39 UNITED Ferrexpo 0.15 UNITED KINGDOM KINGDOM KINGDOM Amigo Holdings 0.09 UNITED Clarkson 0.17 UNITED Fidelity China Special Situations 0.21 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.43 UNITED Close Brothers Group 0.62 UNITED Fidelity European Values 0.25 UNITED KINGDOM KINGDOM KINGDOM Ashmore Group 0.36 UNITED CLS Holdings 0.09 UNITED Fidelity Special Values 0.13 UNITED KINGDOM KINGDOM KINGDOM Assura 0.33 UNITED Coats Group 0.3 UNITED Finsbury Growth & Income Trust 0.36 UNITED KINGDOM KINGDOM KINGDOM Auto Trader Group 1.07 UNITED Cobham 0.72 UNITED FirstGroup 0.29 UNITED KINGDOM KINGDOM KINGDOM Avast 0.18 UNITED Computacenter 0.23 UNITED Fisher (James) & Sons
    [Show full text]
  • Markit Itraxx Europe Series 23 Coupons
    Markit iTraxx Europe Series 23 Final Membership List 16 March 2015 Markit iTraxx Europe Series 23 Contents Markit iTraxx Europe Series 23 Final Membership List ............................................................................................ 3 Markit iTraxx Europe Crossover Series 23 Final Membership List ......................................................................... 6 Markit iTraxx Europe Series 23 Final vs. iTraxx Europe Series 22 .......................................................................... 8 Markit iTraxx Europe Series 23 Coupons ................................................................................................................... 9 Markit iTraxx Europe Series 23 Recovery Rates ....................................................................................................... 9 Copyright © 2015, Markit Group Limited. All rights reserved. www.markit.com 2 Markit iTraxx Europe Series 23 Markit iTraxx Europe Series 23 Final Membership List Sector Markit Ticker Markit Long Name Autos & Industrials AIRBGRO Airbus Group N.V. Autos & Industrials VLVY Aktiebolaget Volvo Autos & Industrials AKZO Akzo Nobel N.V. Autos & Industrials AAUK Anglo American plc Autos & Industrials ATSPA ATLANTIA S.P.A. Autos & Industrials BAPLC BAE SYSTEMS PLC Autos & Industrials BASFSE BASF SE Autos & Industrials BYIF Bayer Aktiengesellschaft Autos & Industrials BMW Bayerische Motoren Werke Aktiengesellschaft Autos & Industrials BOUY BOUYGUES Autos & Industrials BRISCON BRISA - CONCESSAO RODOVIARIA, S.A. Autos
    [Show full text]
  • Market Tracker Trend Report Trends in UK Equity Capital Markets
    Lexis ®PSL Corporate. Market Tracker Trend Report Trends in UK Equity Capital Markets May 2018 ECM Trend Report 1 Contents 1 Scope 2 Industry sectors 3 IPO summary 4 IPOs on the Main Market 13 IPOs on AIM 20 Secondary offerings 39 Looking forward 42 List of deals included in this report 53 LexisPSL Corporate team 54 Contributors Find more Market Tracker Trend Reports and sign up to receive them free by email at lexisnexis.co.uk/MTTR/ECM18 ECM Trend Report 2 Scope Background and approach This report aims to provide an insight into the current dynamics of equity capital market (ECM) activity within the United Kingdom and what we can expect to see in 2018. LexisNexis Market Tracker has conducted research to examine current market trends in respect of ECM transactions during 2017, using 2015 and 2016 ECM transactions for comparative purposes. We reviewed a total of 699 transactions on the London Markets: 161 initial public offers (IPOs) (80 on the Main Market, 81 on AIM), and 538 secondary offers (301 on the Main Market, 237 on AIM). The percentages included in the report have been rounded up or down as appropriate. Accordingly, the percentages may not in aggregate add up to 100%. Where gross proceeds have been calculated, the figures refer to the gross proceeds received by the company and not the total gross proceeds raised, except where indicated otherwise. Trend report thresholds Our thresholds are defined by the scope of the transactions covered by LexisPSL Market Tracker: > Main Market IPOs with a market capitalisation of £100 million or more on admission > AIM IPOs with a market capitalisation of £25 million or more on admission > Secondary offerings (placings, open offers, offers for subscription and rights issues) raising £10 million or more for the company Transfers from AIM to the Main Market and introductions are not included.
    [Show full text]